


# Share the **VISION**

## Opportunity Snapshot

**OVER 67 MILLION people suffer from glaucoma** worldwide. Over **63,000 new cases** are diagnosed each year. If left untreated, glaucoma leads to blindness.



Glaucoma is caused by fluid pressure build up within the eye.  
There is no cure for glaucoma.

The best therapy is to reduce the fluid pressure to arrest damage to the optic nerve.

Current drug treatments come with hefty side effects, low compliance (patients not taking the drugs as prescribed) and low success among certain populations.

- **People with glaucoma need a non-invasive and effective adjunct treatment.**
- **Healthcare providers need improved efficiency and more effective treatments.**

**Ophthalmic International has developed and patented a procedure to treat glaucoma. It's called PNT<sup>1</sup>.**

PNT is a non-invasive procedure that reduces and stabilizes fluid pressure in the eye — a simple 2-minute treatment at the doctor's office every 3-4 months!

It shows little or no known side effects and has proven effective against the type of glaucoma that represents about 75% of diagnosed cases.

It's also an effective treatment for *ocular hypertension*, a condition that may lead to glaucoma.

PNT has been shown to reduce or even eliminate the need for additional drug therapies. Approximately 50% of responders have their drug therapy eliminated, with the remaining 50% can have their medication reduced.

### What's Next?

After ten years research, development and testing and an \$12-million investment, we're now ready to move towards full-scale, worldwide distribution.

That begins with explaining the procedure to the specialists who treat glaucoma and obtaining approvals from healthcare authorities around the world.

Our business plan for the period 2010-2014 projects total revenues for the five-year period of \$240 million, with over \$163-million in net earnings before taxes. For accredited investors, this represents a very attractive investment proposition that commends itself for immediate consideration.

**We've already started the marketing process.** Distribution agreements are already in place for France, Italy, Spain, Portugal, Poland, Serbia, Canada and China. We're in negotiations for distribution to the remainder of the EU, Turkey and Brazil. *To date, our distributors have invested over \$6.3 million in international market development.*

Our business plan contains the details of this attractive investment opportunity. We hope you'll take the time to review it and call us with any questions.

**Sunridge International Inc. Trading symbol ( SNDZ )**

<sup>1</sup> **PN**eumatic Trabeculoplasty. It's a treatment that applies suction to the surface of the eye that is believed to stimulate the body's natural drainage network to lower fluid pressure.